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Abstract
The purpose of an F1000 review is to reflect on the bigger picture, exploring
controversies and new concepts as well as providing opinion as to what is
limiting progress in a particular field. We reviewed about 200 titles published in
2015 that included reference to ‘skeletal muscle, exercise, and ageing’ with the
aim of identifying key articles that help progress our understanding or research
capacity while identifying methodological issues which represent, in our
opinion, major barriers to progress. Loss of neuromuscular function with
chronological age impacts on both health and quality of life. We prioritised
articles that studied human skeletal muscle within the context of age or
exercise and identified new molecular observations that may explain how
muscle responds to exercise or age. An important aspect of this short review is
perspective: providing a view on the likely ‘size effect’ of a potential mechanism
on physiological capacity or ageing.
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Introduction
Identification of effective strategies to substantially improve 
‘health span’ in humans would revolutionise current approaches 
to health care. Rather than the current focus on the develop-
ment of diverse therapies for treating individual age-correlated 
diseases (cancer, heart disease, and dementia), a strategy that posi-
tively impacted on the ageing process would in theory postpone 
disease. During this extended period of absence from illness, sus-
tained functional capacities (for example, muscle strength and 
cognitive status) would be key components of ‘healthy ageing’. In 
turn, these two functional capacities (or approximate correlates) 
represent key clinical measures that are often used to define the 
ageing process. There is extensive evidence that exercise capacity 
(an integrated property of neuromuscular, metabolic and cardio-
vascular function) is under strong genetic as well as environmental 
influence. Indeed, key components of exercise capacity (for 
example, aerobic capacity) vary regardless of the observed range 
of exercise behaviours1 in older adults.
In fact, the role of genotype influencing ‘intrinsic’ exercise 
capacity coupled with the impact of genetics on adaptation to 
exercise training2 is not the only complication for studying human 
ageing. The impact of population stratification on the interpretation 
of cross-sectional analyses exploring the mechanisms for muscu-
loskeletal ageing is typically under-appreciated. For example, over 
30% of all cancer-related deaths occur before the age of 64 years 
(www.cdph.ca.gov), meaning that this subpopulation of individu-
als can never be included in a cohort of subjects who were at least 
70 years old. Notably, the molecular biology of tumour growth 
and muscle responses to exercise share many common effectors 
(for example, mechanistic target of rapamycin [mTOR] signalling 
and pro-angiogenic genes). Furthermore, the ever-popular research 
strategy3 of comparing the health (or physiology) of sedentary older 
people (at least 70 years old) with life-long exercisers does not 
represent an easily interpretable experimental design (for genetic 
and behavioural reasons). Thus, studying the interaction among 
individual rates of biological ageing4, exercise behaviour, and 
molecular factors, including genetics, is clearly non-trivial, and 
greater caution must be shown when claiming that exercise per se 
impacts on ageing or health in the elderly. In the present review, 
we selected about 50 articles from the more than 200 titles pub-
lished during 2015 that refer to the topic of ‘skeletal muscle, age-
ing, and exercise’ with the aim of highlighting new understanding 
or research methods in addition to illustrating technical issues 
which we feel represent barriers to progress. Studies included fur-
ther, robust illustration of the highly variable metabolic adaptation 
noted in response to supervised exercise training5.
Recent human studies that address controversies in 
exercise, ageing, and muscle frailty
The Kraus laboratory5 demonstrated that improvements in insu-
lin action occurred in fewer than half of overweight subjects 
undertaking high-volume aerobic or resistance training. Earlier 
observations found that only the highest training load (something 
equated to the integral of time/volume) of combined aerobic and 
resistance training provided a measureable reduction in the group 
average for indices of glycaemic control6. Interestingly, a cor-
relative analysis this year found that vigorous exercise was most 
closely associated with modest reductions in all-cause mortality7, 
and notably combined resistance and aerobic training will result 
in the exercise sessions including more ‘vigorous’ muscle con-
tractions than those encountered during walking or jogging. 
Nevertheless, older people in better health (for genetic or other 
reasons) will be able and potentially may be more willing to 
undertake vigorous daily physical activity, more so than their 
unhealthy peers, and this can explain the epidemiological corre-
lation between exercise and health in the elderly. To progress our 
understanding of the true relationship between ‘exercise’ and health, we 
need to establish causal mechanisms through randomised clinical tri-
als coupled with global molecular analyses. Such studies will also 
help evolve a more personalised approach to public health.
Use of the term sarcopenia, which refers to ‘age-associated loss 
in muscle tissue’, is relatively new8,9 and there has been limited 
progress in identifying the mechanisms driving sarcopenia in 
humans. Although both nutrition and exercise habits are postu-
lated to contribute to the prevalence of sarcopenia10, recent studies 
state that the overall prevalence remains rather low (approximately 
5% in patients who are at least 70 years old), but this may reflect 
the criteria used and the prevalence may be three times greater 
(but still far from universal). The prevalence of sarcopenia also 
increases with diseases that impact on mobility11. With respect to 
inherent defects within the muscle contributing to sarcopenia, the 
van Loon laboratory found that post-prandial muscle protein syn-
thesis was reduced by approximately 16% in healthy older men 
versus young men12, independently confirming the anabolic resist-
ance concept first identified by Smith and Atherton13. It is interest-
ing to consider whether the process of sarcopenia is substantially 
(quantitatively) influenced by insulin resistance. In 2010, it was 
reported that among 810 Korean subjects, the prevalence of one 
definition of sarcopenia was approximately 16% in subjects with 
diabetes versus approximately 7% in the control subjects by 
60 years of age14. Others have reported that lean mass is approxi-
mately 10% lower in older subjects (about 73 years old) with 
diabetes and that the rate of loss of computed tomography (CT)-
determined thigh cross-sectional area is greater in women, but 
interestingly not in men, with diabetes15. Whether this is reflec-
tive of the molecular features of skeletal muscle in diabetes16 or 
a consequence of physical activity is less clear (given the lack of 
direct measures of exercise); the molecular features of sarcopenia, 
insulin-resistance, and gender need to be compared in detail.
Recently, a meta-analysis by Markofski et al. noted that young 
and old skeletal muscle does not differ in basal (fasting) protein 
synthesis rates but that both total and phosphorylated mTOR (a 
protein complex influencing protein synthesis and breakdown) 
were elevated in muscle from fasted elderly individuals17. This 
may reflect a compensatory response, reflecting increased 
relative muscle loading in daily life (due to reduced muscle strength 
or conditioning) or may reflect dysregulation of the mTOR com-
plex, which influences muscle mass in a complex and non-linear 
manner18. Kirby et al. noted that ‘elderly’ mice subject to syn-
ergist ablation had lower transcription of ribosomal genes 
(downstream of mTOR signalling) compared with young mice and 
that ribosomal gene transcription returned to baseline faster in the 
old mice19. In model organisms, the mTOR inhibitor rapamycin 
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can extend lifespan. Whilst acute rapamycin administration reduces 
translation, data this year indicated that chronic administration 
does not20. More work on the mechanisms underlying rapamycin’s 
effect on lifespan (mTOR mediated and mTOR independent) as 
well as the relevance of changes in translation is required.
Therefore, it is still plausible that older people with less sarco-
penia start off with greater mobility (or less decline) promoting 
retention of muscle mass, rather than the development of ‘sar-
copenia’ being the initiating factor. Adding support to this idea, 
Venturelli et al.21 found that the properties of isolated muscle 
fibres remained intact in frail older people, while Hart et al.22 
found that when physical activity levels were matched (and oxygen 
delivery capacity was similar), no impact of ageing on plantar 
flexor oxidative metabolism was noted, suggesting no ‘inherent’ 
loss of mitochondrial function with age in human muscle. Given 
the modest prevalence (5 to 15% of those over 70 years old depend-
ing on the criteria selected), the contribution of sarcopenia to 
musculoskeletal frailty (impaired function) in old age remains 
unquantified. Further, it seems to us that the role for insulin resist-
ance (or obesity) ‘causing’ sarcopenia or frailty has potentially 
been overstated and only quantitatively modest associations have 
genuinely been observed. For example, Kim et al.23 found that 
CT inter-quartile values for thigh cross-sectional area were 1.7 
to 2.1 in 50 year olds with normal weight and homeostatic model 
assessment insulin resistance (HOMA-IR) but were 1.5 to 2.0 in 
age-matched obese subjects with insulin resistance – hardly a strik-
ing difference. Indeed, after studying 482 adults, Loenneke and 
Loprinzi found that lean body mass was maintained in the face of 
insulin resistance and inflammation24. Overall, this topic is challeng-
ing to address in cross-sectional analyses and using relatively blunt 
instruments (such as dual-energy X-ray absorptiometry [DXA] or 
indeed physical activity questionnaires).
One widely accepted strategy for tackling muscle wasting and 
weakness is supervised resistance exercise training. Neverthe-
less, it is still debated whether older people (at least 70 years old) 
respond in a manner similar to that of younger adults25. Population 
stratification (as a consequence of ‘premature’ deaths, e.g. cancer) 
complicates the evaluation of the efficacy of resistance training with 
respect to human age. This is because up to 25% of healthy adults 
fail to demonstrate any hypertrophy response to long-term resist-
ance training18,26. Interestingly, a study this year described a lack of 
hypertrophy response to 6 months of resistance training in a group 
of otherwise healthy and physically active elderly women (about 68 
years old), while on average muscle strength increased by 20%27. 
The profile of non-responders for gains in function was not reported. 
The development of diagnostics that could ascertain the propor-
tion of non- or low-responders to resistance training in sarcopenic 
elderly populations would help clarify the association between 
molecular potential to ‘grow’ muscle and ability to maintain func-
tion with age. Too many human physiology studies undoubtedly 
report spurious observations owing to small sample sizes and high 
inter-subject variation, while the use of cross-over designs requires 
knowledge of appropriate ‘wash-out’ periods. A valid diagnostic 
could be applied at any age to create a profile of an individual, and 
this could be used to create better-matched ‘case versus control’ 
cohorts, each with equal potential for ‘trainability’ or with similar 
‘intrinsic’ exercise capacities, when evaluating nutrition or lifestyle 
interventions.
However, it must be pointed out that not all researchers agree 
on the scale of heterogeneous outcomes obtained from exercise 
training. The idea that weeks (12 to 24) of supervised resistance 
training could yield ‘non-responders’ was challenged this year28, 
using retrospective analysis of about 200 older men and women. 
The claim that there were no ‘non-responders’ to resistance exer-
cise training was based on the observation that at least one of six 
(inter-related) laboratory parameters changed in every subject 
(multiple strength measures, muscle fibre diameter, and lean mass 
variables). For example, isolated quadriceps muscle function was 
generally improved in all subjects. However, with an everyday physi-
cal test of function (chair-rise time), where accommodation (task 
learning) is less of an issue, there were non-responders. The study 
did not formally consider test-retest variation or accommodation or 
adjust for multiple t tests. Furthermore, although gains in integrated 
muscle function—reflecting improvements in multiple physiologi-
cal factors (for example, coordination, muscle mass, and neuromus-
cular function)—may be more common to most healthy subjects 
with exercise training, whether this is true for older subjects with 
pre-existing skeletal problems or disease (for example, diabetes) 
is less clear25. This returns us to the issue of population strati-
fication, a key challenge for the field to address, ideally using 
larger-scale longitudinal studies and improved diagnostics of an 
individual’s potential to respond to standardised physical training.
Connecting the dots: acute responses that convey 
chronic changes in muscle function
There is an expectation that the molecular and metabolic events 
that occur during and in the minutes after a single bout of exercise 
will, over the period of weeks to months, ‘accumulate’ to cause 
a change in physiological capacity (for example, maximal oxygen 
consumption [VO2 max] and improved insulin-mediated glucose 
clearance). Notably, this ‘accumulative’ concept is somewhat con-
tradicted by data from human studies29. Rather than linear accu-
mulating adaptive changes, change may occur through seemingly 
unrelated secondary molecular responses distinct from acute molec-
ular responses and, critically, be greatly influenced by background 
genetic and epigenetic factors. There is in fact some pre-existing 
evidence that muscle molecular responses to acute-on-chronic 
exercise are rather stochastic29, and this remains one of the most 
active and challenging topics to study in exercise physiology.
Critically, work in this area has, to date, failed to take advantage 
of the inherent heterogeneous ability for out-bred mammals to 
chronically adapt in the face of regular bouts of exercise30,31. In 
short, acute studies should be carried out in subjects that have been 
characterised (either by diagnosis or following training + wash- 
out) for their ability to chronically adapt to the same exercise 
paradigm. If you accept that the much-ignored issue of popula-
tion stratification in the older population can result in a different 
outcome than seen in younger adults (i.e. 75-year-old people are 
not a random sample of all younger adults), then it is feasible that 
individuals presenting with musculoskeletal frailty in older age 
are also those who are less able to mount a muscle hypertrophy 
response18 or have a more blunted response to nutrition throughout 
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life13 or both. Thus, we will need larger, more sophisticated 
studies, as well as studies of longer duration, to properly inves-
tigate what aspects of musculoskeletal ageing are related to 
heterogeneous responses to exercise training or nutrition1.
This year saw the continued search for key molecular ‘targets’ that 
may govern skeletal muscle size or function32. Most new studies in 
2015 focused on consistent molecular responses (group mean dif-
ferences identified by a paired t test) or used inbred murine models, 
where variability is understandably much more limited33. It may be 
more fruitful to stratify acute response against measures of physi-
ological adaptation34. In 2015, two contrasting approaches con-
sidered 5′-AMP-activated protein kinase (AMPK) as a candidate 
transducer for acute-to-chronic adaption. The Wojtaszewski 
group found that functional gains (endurance capacity) with 
4 weeks of training in mice were the same with or without mus-
cle AMPKα1/233 but that acute responses in vascular endothe-
lial growth factor (VEGF) mRNA, a gene involved in vascular 
adaptation35, was apparently reliant on AMPK. This latter interpre-
tation is probably unreliable, as the AMPK knockout (KO) mouse 
did 40% less work during the acute bout and, surprisingly, despite 
also being approximately 50% less physically active, it retained 
normal insulin and glucose control36. It is plausible that 50% of 
normal physical activity in ‘cold mice’37 is sufficient to maintain 
good metabolic health (owing to the very high metabolic turn- 
over), and careful energy balance studies are needed to establish 
whether the room-temperature-housed mouse model can ever 
illuminate mechanisms relevant to human metabolic health.
Genetic and most probably epigenetic factors can influence exer-
cise behaviour and capacity38,39 (for example, altered levels of vol-
untary wheel running [mice] or aerobic capacity). However, the 
appearance of specific phenotypes in genetically manipulated 
mice may or may not reflect the intended genetic manipulation. 
Indeed, controlling variables beyond the targeted gene when gen-
erating transgenic murine models was always deemed complex40 
and nearly impossible to achieve with complete certainty, while 
newer gene editing technology (that is, CRISPR/Cas9) still has off- 
target concerns41 and detection of individual ‘secondary’ molecu-
lar alterations is challenging to spot, as studies are not powered to 
detect each slight off-target event (but additively they can appear as 
altered physiology). However, the absence of any effect on chronic 
adaptation does suggest that AMPK, like PGC1a before it42, is not 
an essential determinant of physiological responses to exercise. 
Of course, if hundreds of clinical studies characterise AMPK or 
PGC1a, then chance associations will still be found (and will be 
more likely to be published). Nevertheless, we would encourage 
investigators to move beyond characterising these ‘usual suspects’. 
In this context, more global (‘unbiased’) research tools provide an 
advantage, particularly when analysed in a responsible manner43. 
Such approaches are more likely to uncover more subtle molec-
ular signatures as statistical models (which accumulate small 
interactions) can be generated, a situation that arguably reflects 
physiological control.
A recent human study profiling a substantial part of the phos-
phoproteome identified AMPK-regulated kinases as being the 
consistent feature of the acute intense cycle exercise in younger 
males34. This study quantified more than 4300 proteins in human 
muscle (note that there are about 40,000 RNA molecules detectable 
in human muscle), identifying many canonical signalling proteins 
(for example, MAPK, PKA, S6 kinase, and Ca2+ response kinases) 
and about 600 phosphopeptides that were modified (with mean 
response statistically consistent). Encouragingly, from our perspec-
tive, they found that about 50% (that is, 50% of the shared variance) 
of the phosphopeptide response to acute exercise was inconsistent 
across subjects, creating the possibility that studying the highly 
variable phosphopeptide responses to muscle contraction can help 
identify factors which contribute to variation in physiological 
adaptation, if such factors are in operation during acute contraction.
The caveat to phosphopeptide measurement technology is that at 
this stage, the overall technical reproducibility of the methodol-
ogy has not been established. Given that the same researchers have 
demonstrated that murine muscle AMPK is not essential for 
physiological adaptation to exercise training33, or fasting glu-
cose and insulin homeostasis for that matter, then the human 
phosphopeptide responses which are unrelated to AMPK could 
transpire to be the most interesting to characterise in future 
human studies. A more detailed discussion of considerations when 
applying proteomics to the study of muscle and exercise can be 
found in Padrão et al.44, and this review indicates that the tech-
nology is very much a ‘work in progress’. In general, alternative 
statistical analysis strategies applied to existing data would be 
beneficial. However, an important challenge is placing the molec-
ular responses within a familiar biological context, as a valid 
pathway or ontology enrichment (although used) is not possi-
ble with ‘proteome’ data because of a lack of knowledge of the 
detectable background (or ‘universe’) of molecules. Without such 
information, the regulated list is merely a subsample of the tis-
sue being studied and invariably yields significant enrichment 
scores versus the ontology database43. Stratification of detected 
molecules against physiological phenotype seems to us the most 
productive strategy for human studies in the shorter term.
Non-coding RNA that has potential to impact on the 
biology of exercise, skeletal muscle, and ageing
Among the most exciting molecular entities contributing to our 
understanding of the complexity of the genome and physiological 
regulation are long non-coding RNAs (lncRNAs). Like 
microRNAs (miRNAs), these transcribed RNAs do not, usually, 
code for protein. Rather, the transcribed product represents the 
active molecular effector, regulating the processing of other RNA 
molecules45 and hence influencing protein expression. lncRNAs 
are not new to skeletal muscle and exercise; it has been almost 
a decade since we identified that the PINK1 antisense RNA 
was regulated by endurance training in humans, altering splic-
ing of PINK1, a metabolic gene linked to Parkinson’s disease45. 
What has changed is the verified scale of lncRNA expression 
(www.noncode.org), and this includes human muscle tissue (for 
example, we routinely detect about 9000 lncRNAs by using 
Affymetrix HTA 2.0 arrays; Affymetrix, Santa Clara, CA, USA). 
The Glass laboratory recently described LncMyoD, a gene able 
to control myoblast proliferation and hence potentially influence 
muscle regeneration from damage46. They identified more than 
1000 intergenic lncRNAs in the murine C2C12 cell line by using 
RNA sequencing data, many regulated during myotube formation 
(it would be interesting to know whether the diversity of expressed 
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lncRNAs is greater in primary muscle cells to better match mus-
cle in vivo). Knockdown of LncMyoD hampered myogenesis, 
reducing the expression of genes expressed in mature muscle 
cells46, indicating a role for LncMyoD in muscle development 
and hence potentially in recovery from injury.
One benefit of research reliant on the detection of RNA molecules 
is that with a little care47, you can be sure of the identity of the 
molecule you are quantifying (a situation far removed from 
antibody-based technologies; see below). However, in the case 
of lncRNAs, the situation is not nearly as simple as one might 
hope. The Olson laboratory this year described a lncRNA related 
to murine exercise performance, but the ‘non-coding’ RNA in this 
case contained a conserved open reading frame that coded for a 
micropeptide that played a role in regulating calcium handling in 
murine ‘fast skeletal muscle’48. So, while one can be sure of the 
identity of the RNA molecule being measured, emerging evidence 
this year49 indicates that a lot of the less-well-characterised ‘non-
coding’ transcriptome may also contain uncharacterised coding 
regions, which in turn yield peptides that impact on physiological 
parameters46,48.
Discoveries in the field of miRNA biology continue and more 
families of these short (about 22 nucleotides) molecules have been 
associated with muscle age or found to be regulated by exercise 
or both50. In humans, in vivo miRNA abundance does not strongly 
co-associate with target mRNA levels but rather protein abun-
dance, which, in combination with transcription, regulates muscle 
phenotype16,51. In our experience, major challenges remain for the 
miRNA field, as the various technology platforms do not consist-
ently measure each miRNA with the same sensitivity or specificity, 
and changes in abundance can be rather modest (supporting our 
model that miRNAs function in a combinatorial manner in vivo 
in adult human muscle and not individually). Thus, whilst short 
non-coding RNA molecules still represent a challenge for all high-
throughput technologies and inconsistencies between the various 
manufacturers’ technologies must be expected (as well as lack of 
conservation of miRNAs between mouse and human), lncRNA 
molecules are easy to reproducibly measure and represent an 
exciting new set of molecules regulating muscle biology.
Protein detection technologies as a barrier to 
research progress
Protein is considered by most physiologists to be the main effec-
tor of function in the cell, yet, unlike RNA, it is very challenging 
to quantify or specifically measure. In muscle biology, a particu-
lar importance is placed on quantification of protein abundance or 
enzyme activity reflecting the contractile and metabolic functions of 
this tissue and historical approaches to studying muscle physiology. 
This has led to a popular—and, we would argue, mistaken—focus 
on individual proteins (for example, AMPK) claimed to regulate 
complex physiological phenotypes and ageing52. It is a simple fact 
that there are fundamental problems associated with how protein 
abundance or activity is quantified, and this has greatly impacted 
on the field of skeletal muscle biology and ageing. Such problems 
include ambiguity over the veracity of the reagents being used to 
quantify key protein factors associated with exercise or muscle 
ageing53. For example, GDF11, a circulating growth and differ-
entiation factor, was claimed to decline with age, ‘controlling’ 
muscle and vascular ageing54, but was in reality misidentified55. 
Pharmacologically, it appears that GDF11 can inhibit the potential 
contribution of skeletal muscle satellite cells to maintenance of adult 
human skeletal muscle56 and so is plausibly related to human 
muscle ageing. In this case, both the GDF11 SOMAmer assay 
(SomaLogic, Boulder, CO, USA) and the GDF11 Abcam Western 
blot antibody (Abcam, Cambridge, UK) cross-reacted with 
myostatin55, altering the described age-related changes in GDF11 
in mice (while no significant changes were noted in rats or 
humans with age56).
So how could such problems be avoided, and why is it a major 
barrier to progress? In the case of GDF11, experiments using tissue 
from GDF11 KO mice demonstrated that the ‘protein detection’ 
technologies were not uniquely detecting GDF11. This simple 
‘litmus test’ for assay specificity (arguably the most useful thing 
one can do with a KO mouse) is not an obligatory prerequisite 
for publication, but this would be a useful development. Manu-
facturers could be obliged to provide the negative control tissues 
and cells to investigators. There is no doubt that lack of specificity 
of detection technologies yielding positive publications can also 
drive needless research efforts on the back of mistaken observa-
tions. For example, although the technical flaws around various 
GDF11 detection technologies have been in the public domain 
since July 2015, and there has been an ongoing and visible debate 
over the validity of any of the available regents57, a raft of cor-
relative studies using GDF11 antibodies have been subsequently 
published without any reference to the controversies58. The scale of 
the problem is substantial; irrespectively of the publication of 
unambiguous evidence proving that the original lab reagents were 
faulty. For example, more than 250 articles reporting ‘measures’ 
of irisin were published between 2014 and 2016 despite multiple 
articles demonstrating the lack of suitability of available protein 
detection reagents59–62. Indeed, there is a substantial challenge in 
‘pausing’ such activity once the proverbial ‘horse has bolted’. 
Therefore, failure to remedy high-profile discoveries59 based on 
flawed protein detection technologies62 is, in our opinion, a major 
barrier to research progress because follow-on research, motivated 
by mistaken observations or worse, is a considerable consumer of 
‘resource’ (that is, researcher time and reagents) that could be bet-
ter utilised to advance the field. If retrospective analysis reveals 
major flaws in published ‘impactful’ research, then editors could 
act more quickly to flag the problems with the original work, 
and in more clear-cut cases a ‘no-blame’ retraction should be 
quickly enforced. Indeed, if strong belief in the original research 
hypothesis remains, this should provide exceptional motivation 
to fully replicate the original study using validated reagents. This 
leaves the finite resources (people and funding) available to study 
human skeletal muscle and ageing better focused on more legiti-
mate hypotheses or observations. Research into ageing, exercise, 
and muscle will by its nature be complex and involve multiple 
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molecular measurement technologies, but further effort to improve 
the specificity of the available tools to quantify protein is, in 
our opinion, a pressing challenge that the field needs to address.
Conclusions
The textbook principles that govern skeletal muscle physiology 
have until recently been developed on studying small homogenous 
unrepresentative healthy males63, coupled with an over-reliance on 
acute exercise studies to study human skeletal muscle phenotype. 
Although it may be understandable (for example, financially), the 
lack of longitudinal studies with detailed phenotyping has also 
meant that our understanding of the impact of ‘ageing’ on human 
skeletal muscle is based on cross-sectional case-control studies. 
One general conclusion is that sooner rather than later there must 
be a shift away from funding small studies to funding larger longi-
tudinal intervention studies capable of delivering more definitive 
answers. Finally, one might also argue that the greatest scrutiny 
should always be placed on any discovery that claims that a ‘sin-
gle’ protein or gene can quantitatively explain ageing or exercise 
performance; extraordinary claims should always require multiple 
independent sources of evidence.
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